1
Jochen G Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou: Methods for inhibiting the activity of the P40 subunit of human IL-12. Abbott & Co KG, McCarter & English, Maria Laccotripe Zacharakis, Jill A Mello, February 8, 2011: US07883704 (50 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an ...


2
Nicholas W Warne, Donna Luisi, Angela Kantor: Anti Aβ antibody formulation. Janssen Alzheimer Immunotherapy, Wyeth, Townsend and Townsend and Crew, December 22, 2009: US07635473 (19 worldwide citation)

The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidan ...


3
Jochen G Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine J Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou: Methods of treatment using human antibodies that bind IL-12. AbbVie, McCarter & English, Maria Laccotripe Zacharakis, Soo Hwa Kim, October 21, 2014: US08865174 (1 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an a ...


4
Li Li, Angela Kantor, Shannon B MacMillan: Stabilizing formulations. Wyeth, Fariba Shoarinejad, October 28, 2014: US08871201 (1 worldwide citation)

Formulations are described that are suitable for storage of proteins, such as antibodies, over a relatively broad range of protein concentrations, pH, and buffer types. Also described are methods of storing a protein and methods of identifying a suitable formulation for storage of a specific protein ...


5
Nicholas W Warne, Donna Luisi, Angela Kantor: Anti A beta antibody formulation. Janssen Alzheimer Immunotherapy, Wyeth, Alston & Bird, November 27, 2012: US08318164

The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidan ...


6
David C Sek, Nicholas W Warne, Kin Ho, Donna L Luisi, Angela Kantor: Use Of Sucrose To Suppress Mannitol-Induced Protein Aggregation. Wyeth, Choate Hall & Stewart Wyeth, August 21, 2008: US20080200656-A1

The present invention provides a method for suppressing mannitol-induced protein aggregation by providing sucrose to a liquid formulation containing a protein. The present invention also provides methods for storing and preparing a liquid formulation containing a protein and a combination of mannito ...


7
Nicholas William Warne, Angela Kantor, Thomas Joseph Crowley, Erin Christine Soley, Li Li, Nicholas Gary Luksha, Edie Anna Neidhardt: Methods for reducing protein aggregation. Wyeth, WilmerHale Wyeth, March 13, 2008: US20080064856-A1

Methods of reducing aggregation of a protein or proteins in a formulation, and protein formulations having reduced aggregation properties are provided. The methods and formulations described herein maintain the biological activity of a protein and increase the shelf life of protein formulations.


8
Li Li, Angela Kantor, Nicholas W Warne: Prediction of relative polypeptide solubility by polyethylene glycol precipitation. Wyeth, WilmerHale Wyeth, January 3, 2008: US20080003686-A1

A method is described for predicting the relative solubility of a polypeptide using polyethylene glycol (PEG) based volume exclusion precipitation. Different polypeptides can be tested for their solubilities relative to each other or relative to a reference. A single polypeptide can be tested for it ...


9
Li Li, Angela Kantor, Nicholas W Warne: Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions. Wyeth, WilmerHale Wyeth, March 20, 2008: US20080070230-A1

Methods of formulating proteins at high concentrations in protein solutions, wherein the protein solutions lack or have reduced liquid-liquid phase separation are described. Such protein solutions are substantially clear and substantially homogenous. Additionally, methods of concentrating and purify ...


10
Jochen G Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou: Human antibodies that bind human IL-12 and methods for producing. Abbott & Co KG, Lahive & Cockfield, March 13, 2008: US20080063634-A1

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an a ...